Browse

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

Last month, Garner Health raised $100 million, vaulting its valuation to $2.7 billion. At first, this startup sounded more like a doctor-rankings company, which I’d typically think of as more ...

Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.